Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | November 28, 2018 | November 30, 2018 |
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director · President and CEO | December 14, 2022 | December 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date November 28, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,333 |
Reported balance
After 2018-11-28 transaction · row 1
1 source rowRow 1 · 2018-11-28 · Exercise / conversion · Acquired 8,333 · Balance 48,333 |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2018-12-22 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-28 · Exercise / conversion · Disposed 8,333 · Balance 0 |
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 428,749 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 428,749 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
NOVAVAX INC
Report date December 14, 2022 · Filed December 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,812 |
Reported balance
After 2022-12-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-14 · Exercise / conversion · Acquired 6,966 · Balance 38,812 F1: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs"). F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Common StockSEC Table I · non-derivative | Direct | 36,492 |
Reported balance
After 2022-12-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-12-14 · Tax withholding · Disposed 2,320 · Balance 36,492 F3: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. F4: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,967 |
Reported balance
After 2022-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-14 · Exercise / conversion · Disposed 6,966 · Balance 6,967 F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F5: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs").
F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F4: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022.
F5: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · derivative · entry 26 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,499 Underlying: Common Stock · 14,000 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F23 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Company Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through each such vesting date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 472 | $190.63 | $89,978.30 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 25 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,879 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F22 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.63 to $190.95, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,502 | $189.47 | $284,584.09 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 24 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.07 to $189.95, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $187.95 | $18,795.00 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 23 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,853 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 8 | $185.71 | $1,485.68 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 22 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,953 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 192 | $183.61 | $35,253.20 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 21 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,961 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.60 to $183.62, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $182.40 | $54,720.99 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 20 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,153 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.88 to $182.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,600 | $181.21 | $289,934.08 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 19 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,453 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.88 to $181.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,541 | $180.42 | $458,457.13 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 18 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,053 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.88 to $180.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,323 | $179.29 | $237,200.01 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 17 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,594 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.87 to $179.84, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,604 | $178.27 | $820,752.78 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 16 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,917 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.82 to $178.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,227 | $177.37 | $1,104,474.27 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 15 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,521 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.80 to $177.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,601 | $176.24 | $458,388.02 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 14 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,748 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.79 to $176.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,602 | $175.15 | $630,877.69 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 13 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,349 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.74 to $175.72, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,853 | $174.30 | $1,020,175.56 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 12 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,951 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.72 to $174.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,002 | $173.16 | $519,833.83 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 11 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,804 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.67 to $173.63, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,103 | $172.02 | $705,815.29 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 10 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,806 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.66 to $172.65, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,602 | $171.34 | $445,814.19 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 9 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,909 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.65 to $171.62, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 901 | $170.07 | $153,233.43 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 8 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,511 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.59 to $170.39, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,959 | $169.05 | $331,174.83 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 7 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,412 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.50 to $169.45, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,801 | $167.88 | $470,240.00 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 6 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,371 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.31 to $168.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,100 | $166.62 | $183,285.96 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 5 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,172 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.30 to $167.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 904 | $165.68 | $149,777.43 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 4 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,272 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.30 to $166.24, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 703 | $164.74 | $115,812.08 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 3 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,176 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.26 to $165.20, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 35,000 | $27.00 | $945,000.00 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 14,000 | $27.60 | $386,400.00 |
DisclosureSEC source: 0001209191-21-059552 · doc4.xml · nonDerivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 26, 2021 Filed Sep 28, 2021 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057939 · doc4.xml · derivative · entry 3 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,546 Underlying: Common Stock · 6,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| September 26, 2021 Filed Sep 28, 2021 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 3,162 | $248.16 | $784,681.92 |
DisclosureSEC source: 0001209191-21-057939 · doc4.xml · nonDerivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,879 Read SEC document |
| September 26, 2021 Filed Sep 28, 2021 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 6,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-057939 · doc4.xml · nonDerivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:14 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050935 · doc4.xml · derivative · entry 1 Erck Stanley C · CIK 0001342826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,439 | $0.00 Strike: $121.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · derivative · entry 30 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,439 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F24 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 6, 2014 grant date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,120 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · derivative · entry 29 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,120 shares Expires 2023-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F23 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 675 | $221.53 | $149,531.47 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 25 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,495 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.38 to $222.33, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 628 | $220.80 | $138,662.78 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 24 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,170 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.34 to $221.20, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,031 | $219.76 | $1,105,615.08 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 23 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,798 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.33 to $220.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 7,423 | $218.77 | $1,623,942.33 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 22 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,829 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.33 to $219.30, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 9,969 | $217.84 | $2,171,651.94 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 21 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,252 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.28 to $218.27, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,994 | $216.92 | $649,454.89 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 20 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,221 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.26 to $217.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,190 | $215.74 | $1,119,693.71 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 19 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,215 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.24 to $216.17, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,466 | $214.76 | $959,109.67 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 18 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,405 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.20 to $215.16, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,355 | $213.38 | $502,521.44 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 17 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,871 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.87 to $213.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 7,616 | $212.29 | $1,616,783.88 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 16 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,226 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.82 to $212.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,242 | $211.21 | $895,946.03 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 15 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,842 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.82 to $211.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,970 | $210.23 | $414,152.90 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 14 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,084 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.75 to $210.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 27,439 | $121.00 | $3,320,119.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 13 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 25,120 | $36.60 | $919,392.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 12 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,560 | $0.00 Strike: $121.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · derivative · entry 28 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,439 Underlying: Common Stock · 17,560 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F24 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 6, 2014 grant date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,879 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · derivative · entry 27 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,120 Underlying: Common Stock · 19,879 shares Expires 2023-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F23 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,181 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · derivative · entry 26 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,181 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F22 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,329 | $215.70 | $286,663.04 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 11 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,495 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.63 to $215.84, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.